Suppr超能文献

HIV感染患者中代偿期丙型肝炎病毒相关性肝硬化的自然史

Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients.

作者信息

Pineda Juan A, Aguilar-Guisado Manuela, Rivero Antonio, Girón-González José A, Ruiz-Morales Josefa, Merino Dolores, Ríos-Villegas María J, Macías Juan, López-Cortés Luis F, Camacho Angela, Merchante Nicolás, Del Valle José

机构信息

Unit of Infectious Diseases, Hospital Universitario de Valme, Hospital Universitario Virgen del Rocío, Seville, Spain.

出版信息

Clin Infect Dis. 2009 Oct 15;49(8):1274-82. doi: 10.1086/605676.

Abstract

OBJECTIVE

To provide information about the incidence and predictors of liver decompensation and death due to liver failure in human immunodeficiency virus (HIV)-infected patients with compensated hepatitis C virus (HCV)-related cirrhosis.

METHODS

Prospective cohort study of 154 HIV-HCV-coinfected patients with a new diagnosis of Child-Pugh-Turcotte (CPT) class A compensated cirrhosis. We evaluated time from diagnosis to the first liver decompensation and death from liver disease, as well as predictors of these outcomes.

RESULTS

Thirty-six patients (23.4%) developed liver decompensation. The incidence of liver decompensation was 6.40 cases per 100 person-years (95% confidence interval [CI], 4.18-9.38 cases per 100 person-years). Factors independently associated with liver decompensation were lack of HCV therapy (hazard ratio [HR], 3.38; 95% CI, 1.09-10.53; P = .035), baseline CD4 cell counts <or=300 cells/mm3 (HR, 2.12; 95% CI, 1.14-5.04; P = .021), CPT score 6 versus 5 (HR, 3.33; 95% CI, 1.39-7.69; P = .007), and a diagnosis of cirrhosis based on data other than biopsy or transient elastography (HR, 2.09; 95% CI, 1.05-4.16; P = .036 ). Fifteen patients (9.7%) died; 11 (73%) of these 15 died from liver disease (mortality due to liver failure, 2.44 deaths per 100 person-years; 95% CI, 1.21-4.36 deaths per 100 person-years). Hepatic encephalopathy as the first liver decompensation (HR, 20.67; 95% CI, 2.71-157.57; P = .003), baseline CD4 count <or=300/mm3 (HR, 0.24; 95% CI, 0.07-0.78; P = 0.17), and baseline CPT score 6 (HR, 4.50; 95% CI, 1.63-12.37; P = .004) were independently associated with liver-related death.

CONCLUSIONS

The incidence of clinical liver events in HIV-HCV-coinfected patients with CPT class A compensated cirrhosis is close to that previously reported in HCV-monoinfected patients. Lower baseline CD4 cell counts, lack of therapy against HCV, and higher CPT score are the factors related to the occurrence of clinical liver events. Minimal changes in CPT score have strong impact in the prognosis of this population.

摘要

目的

提供关于人类免疫缺陷病毒(HIV)感染且患有代偿性丙型肝炎病毒(HCV)相关肝硬化患者肝失代偿及肝衰竭死亡的发生率和预测因素的信息。

方法

对154例新诊断为Child-Pugh-Turcotte(CPT)A类代偿性肝硬化的HIV-HCV合并感染患者进行前瞻性队列研究。我们评估了从诊断到首次肝失代偿和肝病死亡的时间,以及这些结局的预测因素。

结果

36例患者(23.4%)发生肝失代偿。肝失代偿的发生率为每100人年6.40例(95%置信区间[CI],每100人年4.18 - 9.38例)。与肝失代偿独立相关的因素有未进行HCV治疗(风险比[HR],3.38;95% CI,1.09 - 10.53;P = 0.035)、基线CD4细胞计数≤300个/立方毫米(HR,2.12;95% CI,1.14 - 5.04;P = 0.021)、CPT评分为6分与5分相比(HR,3.33;95% CI,1.39 - 7.69;P = 0.007),以及基于活检或瞬时弹性成像以外的数据诊断为肝硬化(HR,2.09;95% CI,1.05 - 4.16;P = 0.036)。15例患者(9.7%)死亡;这15例中的11例(73%)死于肝病(肝衰竭死亡率为每100人年2.44例;95% CI,每100人年1.2I - 4.36例)。以肝性脑病作为首次肝失代偿(HR,20.67;95% CI,2.71 - 157.57;P = 0.003)、基线CD4计数≤300/立方毫米(HR,0.24;95% CI,0.07 - 0.78;P = 0.017)和基线CPT评分为6分(HR,4.50;95% CI,1.63 - 12.37;P = 0.004)与肝病相关死亡独立相关。

结论

CPT A类代偿性肝硬化的HIV-HCV合并感染患者临床肝脏事件的发生率与先前报道的HCV单感染患者相近。较低的基线CD4细胞计数、未进行HCV治疗以及较高的CPT评分是与临床肝脏事件发生相关的因素。CPT评分的微小变化对该人群的预后有强烈影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验